FDA Status of Compounded Ketamine Troches

Are Ketamine Troches FDA-Approved?

The short answer is no. Compounded ketamine troches are not FDA-approved drug products. There is no commercially manufactured, FDA-approved ketamine troche or sublingual ketamine lozenge currently on the market in the United States. The only FDA-approved ketamine-derived psychiatric medication is esketamine (Spravato), a nasal spray approved in 2019 for treatment-resistant depression and major depressive disorder with suicidal ideation.

This does not mean ketamine troches are illegal. They exist within a distinct and well-established legal framework — pharmaceutical compounding — that allows licensed pharmacists to prepare customized medications under specific conditions. But patients and prescribers need to understand what "not FDA-approved" means in practice.

The Legal Basis: Section 503A of the FDCA

The Federal Food, Drug, and Cosmetic Act (FDCA) Section 503A, as amended by the Drug Quality and Security Act of 2013, establishes the legal framework under which compounding pharmacies can prepare medications for individual patients without FDA approval of the final product. To qualify under 503A, a pharmacy must:

• Compound the drug pursuant to a valid prescription for an individually identified patient
• Use API (active pharmaceutical ingredient) obtained from an FDA-registered supplier
• Comply with USP compounding standards (USP 795 for non-sterile products)
• Be licensed by the state board of pharmacy
• Not compound drugs that are essentially a copy of a commercially available product

Compounded ketamine troches meet these criteria because there is no commercially available sublingual ketamine lozenge for the pharmacy to copy. Ketamine HCl is available as an injectable solution (commercially approved for anesthesia), but not as a sublingual lozenge.

The 503B Distinction

Section 503B of the FDCA covers outsourcing facilities — larger-scale compounders who may prepare medications without individual prescriptions for distribution to healthcare facilities. These facilities face higher regulatory scrutiny and must register with the FDA. Most ketamine troches are compounded under 503A (individual prescription basis), not 503B.

What "Not FDA-Approved" Means for Patients

FDA approval means a drug has undergone rigorous clinical trials demonstrating safety and efficacy for specific indications, manufactured under Good Manufacturing Practice (GMP) standards, with labeling reviewed and approved by the FDA. Compounded ketamine troches have not gone through this process.

What this means in practice:

No FDA Review of Formulation

The FDA has not reviewed or approved the specific troche formulation your pharmacy uses. This includes the choice of base material, preservatives, flavoring, and the beyond-use date assigned. Quality depends on the pharmacy's own standards and any voluntary accreditation it holds (such as PCAB).

Off-Label Prescribing

Ketamine itself is FDA-approved as an anesthetic agent. Prescribing it as a compounded troche for depression, anxiety, PTSD, or chronic pain represents off-label prescribing — legal and common in medicine, but relying on clinical evidence rather than FDA-reviewed labeling for the specific use.

Off-label prescribing is the prescriber's professional responsibility. A physician who prescribes ketamine troches off-label should document medical necessity, informed consent, and the clinical rationale in the patient's record.

Insurance Implications

Because compounded ketamine troches are not FDA-approved products, most insurance companies do not cover them. Patients typically pay out of pocket, with costs ranging from $150 to $500 or more per month depending on dose, quantity, and pharmacy. Our insurance and cost guide explains your options in more detail. (The consultation and prescribing fees are separate.)

Prescriber Liability and Responsibilities

When a physician prescribes a compounded drug product, they take on a specific set of professional and legal responsibilities:

Informed Consent

Prescribers should document that they have explained to the patient:

• That the medication is compounded and not FDA-approved
• The evidence base for its use (and any limitations of that evidence)
• Potential risks and benefits
• Alternative treatment options

Choosing a Qualified Pharmacy

The prescriber is legally and ethically responsible for directing the patient to a compounding pharmacy that meets appropriate quality standards. Many ketamine-prescribing practices have relationships with specific PCAB-accredited pharmacies and require patients to use them.

Monitoring Obligations

Off-label prescribing of a controlled substance requires ongoing clinical oversight. This typically means regular follow-up appointments (monthly at minimum for most protocols), tracking of symptoms and adverse effects, and dose adjustments as needed. Our article on monitoring guidelines covers what responsible oversight looks like.

FDA Enforcement Activity and Regulatory Trends

The FDA has issued warning letters to compounding pharmacies that it believes are operating outside the scope of legitimate compounding — for example, by producing large quantities of compounded ketamine without individual prescriptions, or by compounding what the FDA considers an essentially equivalent copy of an approved product.

In 2023, the FDA placed ketamine on its "demonstrably difficult to compound" list for certain sterile dosage forms, though this primarily affected IV formulations rather than oral/sublingual troches. The regulatory environment for compounded ketamine is evolving, and patients and prescribers should stay informed about developments.

State-Level Regulation

State boards of pharmacy also regulate compounding pharmacies within their jurisdiction. Requirements vary significantly by state, which is another reason PCAB accreditation (a voluntary national standard) is a useful quality indicator that transcends state-level variation.

What This Means for Your Safety

The absence of FDA approval does not mean compounded ketamine troches are unsafe. It means:

1. Safety and efficacy are the prescriber's responsibility to assess, using available clinical literature and individual patient evaluation.
2. Quality control is the pharmacy's responsibility, governed by USP standards and any accreditation the pharmacy holds.
3. Ongoing monitoring is essential because there is no FDA-approved labeling with standardized monitoring guidance.

Patients who work with reputable prescribers and PCAB-accredited pharmacies, engage in proper monitoring, and maintain open communication with their care team can receive safe and effective ketamine troche therapy within this framework.

Key Takeaways

• Compounded ketamine troches are not FDA-approved drug products.
• They are legal under Section 503A of the FDCA, which permits patient-specific compounding by licensed pharmacies.
• Prescribing ketamine troches is legal off-label prescribing, but carries informed consent and monitoring obligations for the prescriber.
• The absence of FDA approval means quality depends on pharmacy standards — choose PCAB-accredited pharmacies.
• Insurance typically does not cover compounded ketamine troches.
• The regulatory landscape is evolving; stay in communication with your provider about any changes.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches